Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Hepatology. 2022 Apr 7;75(6):1604–1626. doi: 10.1002/hep.32447

Table 4.

Ongoing and planned clinical trials combining or comparing systemic immunotherapy with TACE.

Trial/Identifier Phase BCLC Stage Treatment Arms Primary Endpoint(s) Setting
ABC-HCC/ NCT04803994 Phase 3 B

  • Atezolizumab + bevacizumab

  • TACE

  • Time to failure of treatment strategy

 First-line
CheckMate 74W/ NCT04340193 (not yet recruiting) Phase 3 B

  • Nivolumab + ipilimumab + TACE

  • Nivolumab + TACE

  • TACE

  • Time to TACE progression

  • OS

 First-line
EMERALD-1/ NCT03778957 Phase 3 B

  • Durvalumab + TACE

  • Durvalumab + bevacizumab + TACE

  • TACE

  • PFS per RECIST 1.1

 First-line
LEAP-012/ NCT04246177 Phase 3 B

  • Lenvatinib + pembrolizumab + TACE

  • TACE

  • PFS per RECIST 1.1

  • OS

 First-line
RENOTACE/ NCT04777851 (not yet recruiting) Phase 3 B

  • Regorafenib + nivolumab

  • TACE

  • PFS per mRECIST

 First-line
TACE-3/NCT04268888 Phase 2/3 B

  • Nivolumab + TACE/TAE

  • TACE/TAE

  • Time to TACE progression

  • OS

 First-line
TALENTACE Phase 3 B

  • Atezolizumab + bevacizumab + TACE

  • TACE

  • TACE-PFS

  • OS

 First-line

BCLC, Barcelona Clinic Liver Cancer; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours; TACE, transarterial chemoembolization; TAE, transarterial embolization.